Since 2001, Selexis has signed over 20 evaluation agreements with clients in the pharmaceutical, biotechnology and diagnostic industries. Because of Selexis’ ability to dramatically reduce the time it takes to produce high-yield cell mammalian lines, the demand for evaluating the Selexis’ technology platform has increased over the last 12 months.
In April of 2005, at the BioProcess International Conference, Amgen presented its data on using and implementing Selexis' Selexis Genetic Elements™ for increasing recombinant protein production.
Selexis believes the SURE Cell Line DevelopmentSM services and technology will play a critical role in helping companies increase their recombinant protein production thus decreasing the Cost of Goods Sold.
Contact Business Development for more information about Selexis’ SURE Cell Line DevelopmentSM Services, parnerships, development capabilities or other opportunities, please contact :
North America
Selexis Inc.
197 Boston Post Road West
Suite 271
Marlborough, MA 01752
USA
T +1 508 485 9262
F +1 508 485 0609
e-mail: info@selexis.com
Offices:
55 New Montgomery St
Suite 605
San Francisco, CA 94105
USA
T +1 415 362 03 11
F +1 415 543 14 13
e-mail: info@selexis.com
find us on a map
Europe
Selexis SA
18 chemin des Aulx
1228 Plan-les-Ouates
Switzerland
T +41 (0)22 308 93 60
F +41 (0)22 308 93 61
e-mail: info@selexis.com
